Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report)’s stock price dropped 0.3% on Thursday . The company traded as low as $14.05 and last traded at $15.75. Approximately 4,172 shares changed hands during trading, an increase of 69% from the average daily volume of 2,467 shares. The stock had previously closed at $15.80.
Finch Therapeutics Group Price Performance
The firm’s 50 day moving average price is $11.88 and its two-hundred day moving average price is $11.52. The stock has a market cap of $25.36 million, a PE ratio of -1.79 and a beta of 1.30.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Featured Articles
- Five stocks we like better than Finch Therapeutics Group
- How Technical Indicators Can Help You Find Oversold Stocks
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What is MarketRank™? How to Use it
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
